Product image of Melkart (Vildagliptin) supplied by GNH India

Melkart

Active Ingredient:
Vildagliptin
Origin:
EU

Melkart (Vildagliptin)

Vildagliptin, the active ingredient in Melkart, is a DPP‑4 inhibitor presented as a pharmaceutical product for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus.

GNH India supplies Melkart as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Melkart is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus and related therapeutic pathways.

  • Type 2 diabetes mellitus: helps lower blood glucose by enhancing insulin secretion in response to meals.
  • Adjunct to diet and exercise: used together with lifestyle measures to achieve target HbA1c levels.
  • Combination therapy: can be combined with metformin or other antidiabetic agents when monotherapy is insufficient.

How It Works

  • Vildagliptin reversibly inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, endogenous GLP‑1 and GIP levels rise, leading to glucose‑dependent stimulation of insulin release and suppression of glucagon secretion, thereby improving post‑prandial and overall glycemic control.

Side Effects

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Headache: transient cranial discomfort.
  • Dizziness: occasional light‑headedness.
  • Upper respiratory tract infection: mild cold‑like symptoms.
  • Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes.
  • Bullous pemphigoid: rare skin blistering disorder.
  • Acute kidney injury: sudden decline in renal function.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Renal impairment: dose adjustment may be required based on renal function.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Elderly patients: monitor closely for hypoglycaemia, especially when used with other glucose‑lowering agents.
  • Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; dose titration may be needed.
  • Pregnancy and lactation: safety not established; avoid unless clearly indicated.
  • Store at ambient temperature: keep in the original pack, protect from moisture and light.

Avoid Interactions

Vildagliptin may interact with other medicines. Review the following:

Major Interactions (Avoid)

  • Insulin or sulfonylureas: combined use can cause severe hypoglycaemia.
  • Strong CYP2C19 inhibitors (e.g., fluconazole): may increase vildagliptin exposure.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce plasma concentrations of vildagliptin.
  • Digoxin: potential alteration of digoxin levels; monitor therapeutic range.
  • Thiazide diuretics: may affect glucose control; observe blood glucose regularly.

Frequently Asked Questions

Melkart contains vildagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It helps improve blood‑sugar control when used together with diet, exercise and, if needed, other antidiabetic medicines.

Vildagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug increases insulin release and reduces glucagon secretion in a glucose‑dependent manner, leading to lower blood glucose levels.

The appropriate dose of Melkart is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of vildagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Melkart, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Melkart (vildagliptin) shares the same class mechanism as other DPP‑4 inhibitors such as sitagliptin or saxagliptin. Clinical efficacy and safety profiles are broadly comparable, though differences may exist in dosing frequency, renal adjustment requirements and specific drug‑interaction potentials.

Store Melkart at ambient temperature, below 25 °C, in the original packaging. Keep it away from moisture and direct sunlight. Do not use the product after the expiry date printed on the label.

Melkart is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include pancreatitis, severe allergic reactions (e.g., anaphylaxis), hepatic dysfunction and rare skin conditions such as bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling or signs of liver injury.

Melkart should be avoided in patients with known hypersensitivity to vildagliptin or any excipients, in those with severe renal impairment where dosing cannot be safely adjusted, and in individuals where the risk of hypoglycaemia is unacceptably high, such as when combined with high‑dose insulin without proper monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT